Clinical Trials Browser

Phase 1/2 × Ovarian Neoplasms × IT-101 × Clear all

NCT02389985 2020-05-28

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1/2 Terminated

Ovarian Neoplasms